UNSPSC 51181538: Fidarestat

This classification denotes a cyp11b2 gene with the molecular formula C12H10FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8SH8T1164U, chemically known as spiro(4h-1-benzopyran-4,4-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2,5-dioxo-, (2s-cis)- but generally known as fidarestat, which bears US NIH Compound Identifier 160024. European Medicines Agency schedules Fidarestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07624MIG.

UNSPSC 51181538 Fidarestat is a Commodity code covering the procurement of this specific pharmaceutical active ingredient, used primarily in diabetes treatment formulations. State and local governments buy fidarestat through their health departments, correctional health services, public hospital systems, and institutional pharmacy programs to support treatment protocols for incarcerated populations, indigent care programs, and specialized medical facilities. The product is typically solicited as part of larger pharmaceutical supply contracts or standalone specialty-drug procurements where dosage forms and delivery specifications are tightly defined.

The source provides no recent state or local contract opportunities tagged to this code, making current market activity difficult to characterize. Without posted RFPs, RFQs, IBFs, or ITBs naming fidarestat as a line item or primary procurement objective, geographic concentration and issuing-body patterns cannot be established from recent solicitation data. State and local health procurement offices may source this ingredient through group purchasing organizations, pharmaceutical cooperative agreements, or national contracts rather than individual public solicitations, limiting visibility in standard procurement channels.